Imara Inc. (IMRA): Price and Financial Metrics


Imara Inc. (IMRA): $1.15

-0.09 (-7.26%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IMRA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IMRA Stock Price Chart Interactive Chart >

Price chart for IMRA

IMRA Price/Volume Stats

Current price $1.15 52-week high $9.29
Prev. close $1.24 52-week low $0.97
Day low $1.15 Volume 97,400
Day high $1.24 Avg. volume 306,120
50-day MA $1.40 Dividend yield N/A
200-day MA $2.56 Market Cap 30.22M

Imara Inc. (IMRA) Company Bio


Imara, Inc. engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. Its product candidate, IMR-687 is a highly selective and small molecule inhibitor of PDE9. The company was founded by James G. McArthur in 2016 and is headquartered in Cambridge, MA.


IMRA Latest News Stream


Event/Time News Detail
Loading, please wait...

IMRA Latest Social Stream


Loading social stream, please wait...

View Full IMRA Social Stream

Latest IMRA News From Around the Web

Below are the latest news stories about IMARA Inc that investors may wish to consider to help them evaluate IMRA as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

With the long weekend over it's time to start another week of trading with the biggest pre-market stock movers for Tuesday!

William White on InvestorPlace | February 22, 2022

David Mott Is The Independent Chairman of IMARA Inc. (NASDAQ:IMRA) And They Just Picked Up 144% More Shares

Even if it's not a huge purchase, we think it was good to see that David Mott, the Independent Chairman of IMARA Inc...

Yahoo | February 19, 2022

Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that Rahul Ballal, Ph.D., President and Chief Executive Officer, will participate in a Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference taking place virtually on Thursday, February 17, 2022 at 3:40 p.m. ET.

GlobeNewswire | February 10, 2022

Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)

Expanding patient base and potential of Imara''s small molecule oral inhibitor of phosphodiesterase-9 (PDE9) alongside hemoglobin disorders Phase 2 trial aims to select HFpEF patients with enriched PDE9 expression for targeted approach to a heterogeneous disease Study initiation planned for second quarter of 2022 BOSTON, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ: IMRA ), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for tovinontrine (IMR-687) to commence clinical development for the treatment of heart failure with...

Benzinga | January 25, 2022

Imara To Start Testing Tovinontrine In Heart Failure Patients

The FDA signed off Imara Inc's (NASDAQ: IMRA) investigational new drug (IND) application for tovinontrine (IMR-687) in heart failure with preserved ejection fraction (HFpEF). The Company plans to initiate a Phase 2 trial in Q2 of 2022 to evaluate tovinontrine in patients 45 years of age or older with persistent HFpEF symptoms. The Phase 2 HFpEF trial will be a randomized, placebo-controlled study of approximately 170 patients. Trial subjects will be dosed for 16 weeks. The primary endpoint will

Yahoo | January 25, 2022

Read More 'IMRA' Stories Here

IMRA Price Returns

1-mo -16.67%
3-mo -23.33%
6-mo -62.78%
1-year -84.18%
3-year N/A
5-year N/A
YTD -48.89%
2021 -89.80%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5523 seconds.